Overview

Palbociclib + Ganitumab In Ewing Sarcoma

Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: - Palbociclib - Ganitumab
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
1 Million 4 Anna Foundation
Alan B. Slifka Foundation
Carson Sarcoma Foundation
ChemoWarrior: the eli sidler foundation
i-ROK Foundation
Rutledge Cancer Foundation
Teaming up to Fight Childhood Cancer
Treatments:
Antibodies, Monoclonal
Palbociclib